VALN
Valneva SE - ADR

2,069
Loading...
Loading...
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older. The DUKORAL is a drinkable vaccine that helps prevent diarrhea caused by heat-labile toxin-producing ETEC, as well as cholera. The IXCHIQ is a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
713

Frequently Asked Questions

What is Market Cap of Valneva SE - ADR?
What is the 52-week high for Valneva SE - ADR?
What is the 52-week low for Valneva SE - ADR?
What is Valneva SE - ADR stock price today?
What was Valneva SE - ADR stock price yesterday?
What is the PE ratio of Valneva SE - ADR?
What is the Price-to-Book ratio of Valneva SE - ADR?
What is the 50-day moving average of Valneva SE - ADR?
How many employess does Valneva SE - ADR has?

Latest VALN News

View

Advertisement. Remove ads.

Advertisement. Remove ads.